UNSPSC 51162747: Xylometazoline

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H24N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) WPY40FTH8K, chemically known as 2-imidazoline, 2-(4-tert-butyl-2,6-dimethylbenzyl)- but more generally known as xylometazoline, which bears US NIH Compound Identifier 5709. European Medicines Agency schedules Xylometazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00122MIG.

UNSPSC 51162747 Xylometazoline, a Commodity code, nominally covers a single nasal decongestant active pharmaceutical ingredient, but recent state and local solicitations tagged with this code show minimal or no direct purchasing activity for xylometazoline itself. Instead, the opportunities posted under this code involve broader pharmaceutical and drug-response product procurement—naloxone acquisition for overdose reversal and generic multi-source pharmaceuticals distributed through cooperative purchasing vehicles. State and local issuing bodies using this code include county health departments (Seminole County, Florida) and multistate cooperative purchasing alliances administered by state procurement offices (Minnesota Department of Administration's Office of State Procurement, serving MMCAP members across multiple states including Oregon). The scope reflects emergency-response and general pharmaceutical distribution rather than targeted xylometazoline procurement, suggesting either miscoding of these opportunities or extremely limited direct demand for the ingredient at state and local level.

Geographic activity centers on Florida and the Upper Midwest (Minnesota and Oregon as named MMCAP participants), with Seminole County's naloxone IFB (posted June 30, 2026, due July 26, 2023 per source) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (posted January 20, 2026, due March 26, 2026) establishing contracts effective July 1, 2026 across participating state and local facilities. Neither opportunity directly targets xylometazoline, indicating that the code may see limited relevant procurement activity or that recent state and local buyers are coding broader pharmaceutical acquisitions to this ingredient code despite the mismatch in actual scope.